Management of Organophosphate‑Induced Delayed Neuropathy (OPIDN)

Diagnostic Considerations

Exclude alternative neuropathies – In adults presenting with delayed neuropathy after organophosphate exposure, clinicians should rule out chemotherapy‑induced peripheral neuropathy, diabetic neuropathy, and other toxic neuropathies through a focused history and targeted investigations. Evidence level: low (expert opinion) 1

Neuropathic pain management – Treat OPIDN‑related neuropathic pain with standard agents such as gabapentin, pregabalin, or duloxetine; no OPIDN‑specific efficacy data are available. Evidence level: low (extrapolation from general neuropathy studies) 1

Immediate removal from organophosphate work – Workers diagnosed with OPIDN must be withdrawn from any further organophosphate exposure to prevent worsening of axonal injury. Evidence level: moderate (consensus of occupational health experts) 2
Occupational health referral – Coordinate with occupational medicine to evaluate workplace safety practices and implement protective measures for the affected worker and coworkers. Evidence level: moderate (consensus of occupational health experts) 3

Atropine and pralidoxime are not indicated – These agents are effective only for acute cholinergic crisis and have no therapeutic role once OPIDN has developed. Evidence level: high (expert consensus based on mechanistic understanding) [4][5]
Cholinesterase levels should not guide OPIDN care – Because OPIDN results from irreversible inhibition of neuropathy target esterase (NTE) rather than acetylcholinesterase, serum cholinesterase measurements do not predict or monitor the delayed neuropathy. Evidence level: high (expert consensus) 5